ATE422943T1 - Verfahren und verbindungen zur verstärkung der fybrozyten-bildung - Google Patents

Verfahren und verbindungen zur verstärkung der fybrozyten-bildung

Info

Publication number
ATE422943T1
ATE422943T1 AT03800146T AT03800146T ATE422943T1 AT E422943 T1 ATE422943 T1 AT E422943T1 AT 03800146 T AT03800146 T AT 03800146T AT 03800146 T AT03800146 T AT 03800146T AT E422943 T1 ATE422943 T1 AT E422943T1
Authority
AT
Austria
Prior art keywords
fybrocyte
enhancing
compounds
formation
methods
Prior art date
Application number
AT03800146T
Other languages
English (en)
Inventor
Richard Gomer
Darrell Pilling
Original Assignee
William Marsh Rice Univeristy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice Univeristy filed Critical William Marsh Rice Univeristy
Application granted granted Critical
Publication of ATE422943T1 publication Critical patent/ATE422943T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT03800146T 2002-12-23 2003-12-22 Verfahren und verbindungen zur verstärkung der fybrozyten-bildung ATE422943T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43604602P 2002-12-23 2002-12-23
US43602702P 2002-12-23 2002-12-23
US51577603P 2003-10-30 2003-10-30
US51946703P 2003-11-12 2003-11-12
US52517503P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
ATE422943T1 true ATE422943T1 (de) 2009-03-15

Family

ID=32686361

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03814319T ATE500839T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung
AT03800146T ATE422943T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur verstärkung der fybrozyten-bildung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03814319T ATE500839T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung

Country Status (13)

Country Link
US (3) US7935682B2 (de)
EP (3) EP1596880B1 (de)
JP (4) JP4819364B2 (de)
AT (2) ATE500839T1 (de)
AU (2) AU2003299873A1 (de)
CA (2) CA2509241C (de)
CY (1) CY1111536T1 (de)
DE (2) DE60336347D1 (de)
DK (1) DK1596880T3 (de)
ES (1) ES2318195T3 (de)
IL (1) IL169258A0 (de)
PT (1) PT1596880E (de)
WO (2) WO2004058292A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935682B2 (en) 2002-12-23 2011-05-03 William Marsh Rice University Wound healing dressing for enhancing fibrocyte formation
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
WO2007094776A1 (en) * 2006-02-15 2007-08-23 William Marsh Rice University Compositions and methods for suppressing fibrocyte differentiation
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US8642307B2 (en) * 2006-05-25 2014-02-04 Nalge Nunc International Corporation Cell culture surface chemistries
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8114608B2 (en) * 2006-11-30 2012-02-14 University Of Virginia Patent Foundation Methods for treating and diagnosing fibrotic and fibroproliferative diseases
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
CN105037535A (zh) * 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
AU2010224170B2 (en) 2009-03-11 2015-12-24 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
AU2010232591A1 (en) * 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2443144T3 (en) * 2009-06-17 2015-11-23 Promedior Inc SAP variants and their application
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
EP2571903B1 (de) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulusreaktive polymere zur aufreinigung von biomolekülen
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
EP2790690A4 (de) * 2011-12-14 2015-08-12 Texas A & M Univ Sys Zusammensetzungen und verfahren zur verwaltung neutrophiler bewegungen unter verwendung des serum-amyloids p (sap)
EP2793927B1 (de) * 2011-12-21 2019-03-06 Promedior, Inc. Serum-amyloid-p-antikörper-fusionsproteine
WO2014112125A1 (ja) * 2013-01-21 2014-07-24 三菱電機株式会社 電気機器識別システム、電気機器、及び、電気機器識別方法
EP2968556A1 (de) * 2013-03-13 2016-01-20 University Of Kentucky Research Foundation Verfahren zur verabreichung von igg1-antikörpern und verfahren zur unterdrückung von angiogenese
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
EP3413881B1 (de) * 2016-02-08 2021-06-30 Hackensack University Medical Center Zusammensetzungen und verfahren zur behandlung von chronischen wunden
JP6780600B2 (ja) * 2017-07-28 2020-11-04 株式会社デンソー 内燃機関制御システム

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
DE2725261C2 (de) 1977-06-03 1986-10-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
EP0476721B1 (de) * 1987-11-20 1995-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Methode zur Entfernung von Serum-Amyloid-Protein
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
WO1997026906A1 (en) * 1996-01-25 1997-07-31 Svehag Sven Erik Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
HUP0100929A3 (en) 1998-02-17 2005-10-28 Celldex Therapeutics Inc Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
EP1090630A4 (de) 1998-03-11 2004-06-16 Soken Kk Hautnormalisierungsmittel
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001074300A1 (en) 2000-03-30 2001-10-11 Brennen Medical, Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002098278A2 (en) * 2001-06-04 2002-12-12 Cytokine Pharmasciences, Inc Peripheral blood fibrocytes differentiation pathway and migration to wound sites
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
EP1534335B9 (de) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US7935682B2 (en) * 2002-12-23 2011-05-03 William Marsh Rice University Wound healing dressing for enhancing fibrocyte formation
MXPA06011796A (es) 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
AU2005244058B2 (en) 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof
CA2568661A1 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)

Also Published As

Publication number Publication date
JP2006514654A (ja) 2006-05-11
AU2003299873A2 (en) 2008-02-28
ATE500839T1 (de) 2011-03-15
PT1596880E (pt) 2011-06-06
EP1576368A2 (de) 2005-09-21
AU2003300266A2 (en) 2008-02-21
JP2014141512A (ja) 2014-08-07
CA2509241A1 (en) 2004-07-15
EP1576368B1 (de) 2009-02-18
US7666432B2 (en) 2010-02-23
EP1596880A2 (de) 2005-11-23
IL169258A0 (en) 2007-07-04
JP4922560B2 (ja) 2012-04-25
WO2004059318A3 (en) 2005-05-06
DK1596880T3 (da) 2011-06-14
DE60326273D1 (de) 2009-04-02
CA2509241C (en) 2013-07-30
EP1596880B1 (de) 2011-03-09
WO2004058292A3 (en) 2004-10-28
JP4819364B2 (ja) 2011-11-24
WO2004059318A2 (en) 2004-07-15
AU2003300266B2 (en) 2009-10-08
CA2509392A1 (en) 2004-07-15
DE60336347D1 (de) 2011-04-21
WO2004058292A2 (en) 2004-07-15
US7935682B2 (en) 2011-05-03
ES2318195T3 (es) 2009-05-01
US20060002938A1 (en) 2006-01-05
JP2006511586A (ja) 2006-04-06
US20050238620A1 (en) 2005-10-27
WO2004058292A8 (en) 2005-08-25
AU2003300266A1 (en) 2004-07-22
JP2011016824A (ja) 2011-01-27
CY1111536T1 (el) 2015-10-07
AU2003299873A1 (en) 2004-07-22
US20110311554A1 (en) 2011-12-22
US8187599B2 (en) 2012-05-29
EP2017617A1 (de) 2009-01-21

Similar Documents

Publication Publication Date Title
ATE422943T1 (de) Verfahren und verbindungen zur verstärkung der fybrozyten-bildung
ATE497778T1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
ATE409037T1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
ATE318820T1 (de) Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ATE552842T1 (de) Verwendung von plasminogen zur wundheilung
DE69902154T2 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
DE60212613D1 (de) Doxycyclin zur behandlung von akne
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60040523D1 (de) Methoden zur behandlung von nägeln
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
ATE278441T1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE602007010459D1 (de) Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
EE200300580A (et) Meetod ja inertse absorbeeriva savi kasutamine segu töötlemiseks ning saadus
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties